Skip to main content
Log in

Effects of price cap regulation on pharmaceutical supply chain under the zero markup drug policy

  • Original Paper
  • Published:
Operational Research Aims and scope Submit manuscript

Abstract

In 2009, China initiated a zero-markup for drugs (ZMD) policy to prevent profit-oriented behaviors among the healthcare providers and alleviate the financial burden on patients. However, overtreatment still prevails because pharmaceutical producers barrage the doctor-patient relationship with promotional activities. This study considered a pharmaceutical supply chain composed of one pharmaceutical producer and one healthcare provider in the context of the ZMD policy, seeking to derive the optimal decisions of the supply chain by considering three scenarios: (1) no promotional activities or price cap regulation; (2) promotional activities but no price cap regulation; and (3) promotional activities and price cap regulation. By comparing the equilibria of these scenarios, we evaluated the impacts of the producers' promotional activities on supply chain members' decisions, profits, and social welfare, as well as the intervention role played by price cap regulation. Our results indicate that the producers' promotional activities contribute to overtreatment, thereby negatively affecting social welfare and patients with low to moderate financial resources. However, the implementation of price cap regulation can effectively reduce the extent of producers' promotional activities, curb overtreatment, and mitigate the associated harm to social welfare.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  • Alev I, Atasu A, Toktay LB, Toktay B (2022) Extended producer responsibility for pharmaceuticals. Manuf Serv Oper Manag 24(1):524–541

    Google Scholar 

  • Arrow KJ (1963) Uncertainty and the welfare economics of medical care. Am Econ Rev 82(2):141–149

    Google Scholar 

  • Bates LJ, Santerre RE (2013) Does the US health care sector suffer from Baumol’s cost disease? Evidence from the 50 states. J Health Econ 32(2):386–391

    Google Scholar 

  • Bennett D, Yin W (2019) The market for high-quality medicine: retail chain entry and drug quality in India. Rev Econ Stat 101(1):76–90

    Google Scholar 

  • Blomqvist A (1991) The doctor as double agent: Information asymmetry, health insurance, and medical care. J Health Econ 10(4):411–432

    Google Scholar 

  • Brekke K, Konigbauer I, Straume OR (2007) Reference pricing of pharmaceuticals. J Health Econ 26(3):613–642

    Google Scholar 

  • Brennan TA, Rothman DJ, Blank L, Blumenthal D, Chimonas SC (2006) Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA 295(4):429–433

    Google Scholar 

  • Brownlee S, Garber J (2019) Overprescribed: High cost isn't America's only drug problem. Stat.com.

  • Chander V, Sharma B, Negi V, Aswal R, Singh P, Singh R, Dobhal R (2016) Pharmaceutical compounds in drinking water. J Xenobiot 6(1):1–7

    Google Scholar 

  • Chen X, Li S, Wang X (2020) Evaluating the effects of quality regulations on the pharmaceutical supply chain. Int J Prod Econ 230:107770

    Google Scholar 

  • Chen X, Yang H, Wang X (2018) Effects of price cap regulation on the pharmaceutical supply chain. J Bus Res 97:281–290

    Google Scholar 

  • Dong X, Chintagunta PK, Manchanda P (2011) A new multivariate count data model to study multicategory physician prescription behavior. Quant Mark Econ 9(3):301–337

    Google Scholar 

  • Dranove D (1988) Demand inducement and the physician/patient relationship. Econ Inq 26(2):281–298

    Google Scholar 

  • Dranove D, Spier KE (2003) A theory of utilization review. Contrib Econ Anal Policy 2(1):1–19

    Google Scholar 

  • Dranove D (2011) Health care markets, regulators, and certifiers. Handb Health Econ 2:639–690

    Google Scholar 

  • Eggleston K, Yip W (2004) Hospital competition under regulated prices: application to urban health sector reforms in China. Int J Health Care Finance Econ 4(4):343–368

    Google Scholar 

  • Fittler A, Lanko E, Brachmann B, Botz L (2013) Behavior analysis of patients who purchase medicines on the internet: can hospital pharmacists facilitate online medication safety? Eur J Hosp Pharm 20(1):8–12

    Google Scholar 

  • Godager G, Wiesen D (2013) Profit or patients’ health benefit? Exploring the heterogeneity in physician altruism. J Health Econ 32(6):1105–1116

    Google Scholar 

  • Gorman S, Gorman JM (2018) Why do doctors overprescribe? https://www.Psychology-today.com/us/blog/denying-the-grave/201802/why-do-doctors-overprescribe.

  • Guo T, Sriram S, Manchanda P (2020) The effect of information disclosure on industry payments to physicians. J Mark Res 58(1):115–140

    Google Scholar 

  • He Y, Dou G, Huang Q (2018) Does the leading pharmaceutical reform in China really solve the issue of overly expensive healthcare services? Evidence from an empirical study. PLoS ONE 13(1):e0190320

    Google Scholar 

  • He JA (2014) The doctor–patient relationship, defensive medicine and overprescription in Chinese public hospitals: evidence from a cross-sectional survey in Shenzhen city. Soc Sci Med 123:64–71

    Google Scholar 

  • Hu J, Mossialos E (2016) Pharmaceutical pricing and reimbursement in China: when the whole is less than the sum of its parts. Health Policy 120(5):519–534

    Google Scholar 

  • Jiang B, Ni J, Srinivasan K (2014) Signaling through pricing by service providers with social preference. Mark Sci 33(5):641–654

    Google Scholar 

  • Jiang X, He P, Zhu D, Shi X, Meng Q (2020) Different impacts of the zero-markup drug policy on county general and traditional Chinese medicine hospitals: evidence from Shandong province, China. Int J Equity Health 19:219

    Google Scholar 

  • Kouvelis P, Xiao Y, Yang N (2015) PBM Competition in pharmaceutical supply chain: formulary design and drug pricing. Manuf Serv Oper Manag 17(4):511–526

    Google Scholar 

  • Liu T (2011) Credence goods markets with conscientious and selfish experts. Int Econ Rev 52(1):227–244

    Google Scholar 

  • Luo J, Wen X, Mao Z (2022) Evaluation on the effect of national drug centralized procurement in public medical institutions in Hubei Province. China Health Insurance 2022(10):36–39

    Google Scholar 

  • Ma C, McGuire TG (1997) Optimal health insurance and provider payment. Am Econ Rev 87(4):685–704

    Google Scholar 

  • Modak NM, Panda S, Sana SS (2016) Three-echelon supply chain coordination considering duopolistic retailers with perfect quality products. Int J Prod Econ 182:564–578

    Google Scholar 

  • Nagurney A, Li D, Nagurney LS (2013) Pharmaceutical supply chain networks with outsourcing under price and quality competition. Int Trans Oper Res 20(6):859–888

    Google Scholar 

  • Nassiri S, Adida E, Mamani H (2021) Reference pricing for healthcare services. Manufacturing & service operations management, Forthcoming, MSOM-19-387.

  • Ngok K, Wang C (2016) Is price regulation on drugs used in hospital workable for reducing medical expenditure? Based on the evaluation of the Zero-profit drug policy implanted in county-level public hospitals of Guangdong province. Wuhan University J (philos Soc Sci) 69(2):29–38

    Google Scholar 

  • Ni Z, Jia J, Cui L, Zhou S, Wang X (2021) The impact of China’s zero-markup drug policy on hospitalization expenses for inpatients in tertiary public hospitals: evidence based on quantile difference-in-difference models. Healthcare 9:908

    Google Scholar 

  • Olivella P, Siciliani L (2017) Reputational concerns with altruistic providers. J Health Econ 55:1–13

    Google Scholar 

  • Raza SA (2018) Supply chain coordination under a revenue-sharing contract with corporate social responsibility and partial demand information. J Prod Econ 205:1–14

    Google Scholar 

  • Sher MM, Kim SL, Banerjee A, Paz MT (2018) A supply chain coordination mechanism for common items subject to failure in the electronics, defense, and medical industries. J Prod Econ 203:164–173

    Google Scholar 

  • Uthayakumar R, Priyan S (2013) Pharmaceutical supply chain and inventory management strategies: Optimization for a pharmaceutical company and a hospital. Oper Res Health Care 2(3):52–64

    Google Scholar 

  • Valletti TM (2000) Minimum quality standards under Cournot competition. J Regul Econ 18(3):235–245

    Google Scholar 

  • Wang X, Li F, Wang X et al (2020) Effects of different mark-up drug policies on drug-related expenditures in tertiary public hospitals: an interrupted time series study in Shanghai, China, 2015–2018. Biosci Trends 14(1):16–22

    Google Scholar 

  • Weraikat D, Zanjani MK, Lehoux N (2016) Two-echelon pharmaceutical reverse supply chain coordination with customers incentives. Int J Prod Econ 176:41–52

    Google Scholar 

  • World Bank (2010) Financing, pricing, and utilization of pharmaceuticals in China: the road to reform. Washington, DC

  • Wu B, Zhang Q, Qiao X (2014) Effects of pharmaceutical price regulation: China’s evidence between 1997 and 2008. J Asia Paci Econ 20(2):290–329

    Google Scholar 

  • Yu X, Li C, Shi Y, Yu M (2010) Pharmaceutical supply chain in China: Current issues and implications for health system reform. Health Policy 97(1):8–15

    Google Scholar 

  • Zhang H, Zaric G, Huang T (2011) Optimal design of a pharmaceutical price-volume agreement under asymmetric information about expected market size. Prod Oper Manag 20(3):334–346

    Google Scholar 

  • Zhou X, Li L, Hesketh T (2014) Health system reform in rural China: voices of health-workers and service-users. Soc Sci Med 117:134–141

    Google Scholar 

Download references

Acknowledgements

The authors thank associate editor and anonymous referees for their numerous constructive comments and encouragement that can improve our paper greatly.

Funding

The work was supported by the National Social Science Fund of China [Grant 22CGL020] and the China Postdoctoral Science Foundation [Grant 2023M730501].

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jing Li.

Ethics declarations

Conflict of interest

This manuscript has not been published and is not under consideration for publication elsewhere. The authors declare that there are no conflicts of interest regarding the publication of this article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Appendix

Appendix

1.1 Proof of Proposition 1

Taking the second order derivative of the producer's profit function \({\pi }_{h}\), obtains \(\frac{{d}^{2}{\pi }_{h}}{d{p}_{h}^{2}}=-\frac{2}{1-\delta }<0\). Thus, \({\pi }_{h}\) is strictly concave in \({p}_{h}\). According to the first order condition (FOC), we can get the optimal \({p}_{h}\) from equation (A-1),

$$\frac{d{\pi }_{h}}{d{p}_{h}}=1-\frac{2}{1-\delta }{p}_{h}+\frac{{p}_{l}}{1-\delta }=0.$$
(A-1)

After simplification, we can obtain \({p}_{h}^{b}=\left(1-\delta +{p}_{l}\right)/2\), which, when substituted into the producer's profit function, patients' surplus and social welfare, yields \({\pi }^{b}\), \(C{S}^{b}\) and \({W}^{b}\).

1.2 Proof of Property 1

For the patient's surplus in equilibrium \(C{S}^{b}\), we can get the first order derivative \(\frac{\partial C{S}^{b}}{\partial {p}_{l}}=\frac{2(4-3\delta ){p}_{l}}{8\delta (1-\delta )}-\frac{3}{4}\), \(\frac{\partial C{S}^{b}}{\partial \delta }=\frac{3}{8}-\frac{[4-(8-3\delta )\delta ]{p}_{l}^{2}}{8{(1-\delta )}^{2}{\delta }^{2}}\). According to the condition \(0<{p}_{l}<\frac{\delta \left(1-\delta \right)}{2-\delta }\), we get \(\frac{\partial C{S}^{b}}{\partial {p}_{l}}<-\frac{1}{2\left(2-\delta \right)}<0\) and \(\frac{\partial C{S}^{b}}{\partial \delta }>\frac{1}{4-2\delta }>0\).

For the producer's profit in equilibrium \({\pi }^{b}\), we calculate \(\frac{\partial {\pi }^{b}}{\partial {p}_{l}}=1-\frac{(4-3\delta ){p}_{l}}{2(1-\delta )\delta }\), \(\frac{\partial {\pi }^{b}}{\partial \delta }=-\frac{{\left(1-\delta \right)}^{2}-{p}_{l}^{2}}{4{(1-\delta )}^{2}}\). According to the condition \(0<{p}_{l}<\frac{\delta \left(1-\delta \right)}{2-\delta }\), we obtain \(\frac{\partial {\pi }^{b}}{\partial {p}_{l}}>\frac{\delta }{4-2\delta }>0\) and \(\frac{\partial {\pi }^{b}}{\partial \delta }<0\).

For the social welfare in equilibrium \({W}^{b}\), we get \(\frac{\partial {W}^{b}}{\partial {p}_{l}}=\frac{1}{4}-\frac{(4-3\delta ){p}_{l}}{4\delta (1-\delta )}\) and \(\frac{\partial {W}^{b}}{\partial \delta }=\frac{1}{8}+\frac{(2-\delta )(2-3\delta ){p}_{l}^{2}}{8{(1-\delta )}^{2}{\delta }^{2}}\). According to the same condition, we find that \({W}^{b}\) first increases and then decreases with \({p}_{l}\), \(\frac{1}{4}>\frac{\partial {W}^{b}}{\partial {p}_{l}}>-\frac{1-\delta }{2\left(2-\delta \right)}>0\). When \(\delta <\frac{2}{3}\), there is \(\frac{\partial {W}^{b}}{\partial \delta }>\frac{1}{8}>0\).

1.3 Proof of Proposition 2

Let Eq. (6) greater than or equal to zero, and compare the results to \({u}_{h}\left(\theta \right)\ge 0\), one can easily justify the proposition.

1.4 Proof of Proposition 3

(1) In the situation of \(\eta \le H\left({p}_{h}\right)\), \({\pi }_{h}=({p}_{h}-\eta )(1-\frac{{p}_{h}-{p}_{l}}{1-\delta }+\frac{\eta }{{o}_{d}(1-\delta )})\). We can get the second order derivative \(\frac{{\partial }^{2}{\pi }_{h}}{\partial {\eta }^{2}}=-\frac{2}{{o}_{d}\left(1-\delta \right)}<0\), which indicates that the profit function is concave in the promotional effort \(\eta\) and the optimal solution exists. According to FOC, we get

$$\eta =\frac{1}{2}\left[\left(1+{o}_{d}\right){p}_{h}-{o}_{d}{p}_{l}-\left(1-\delta \right){o}_{d}\right].$$
(A-2)

Substitute (A-2) into the objective function \({\pi }_{h}\), then take the first derivative with respect to \({p}_{h}\), we obtain,

$$\frac{d{\pi }_{h}}{d{p}_{h}}=\frac{\left(1-{o}_{d}\right)\left[\left(1-{o}_{d}\right){p}_{h}+\left(1-\delta +{p}_{l}\right){o}_{d}\right]}{2{o}_{d}\left(1-\delta \right)}>0.$$
(A-3)

The producer's profit will increase with the branded drug price. Thus, under the condition \(\eta \le H\left({p}_{h}\right)\), the optimal solution of \({p}_{h}\) is the boundary solution, satisfying \(\eta =H\left({p}_{h}\right)={o}_{d}\left(\delta {p}_{h}-{p}_{l}\right)\). Then we get \({p}_{h}=\frac{\eta +{o}_{d}{p}_{l}}{\delta {o}_{d}}\).

(2) In the situation of \(\eta \ge H\left({p}_{h}\right)\), \({\pi }_{h}=({p}_{h}-\eta )(1-{p}_{h})\) and take its first order derivative with respect to \(\eta\), yielding

$$\frac{\partial {\pi }_{h}}{\partial \eta }=-\left(1-{p}_{h}\right)<0.$$
(A-4)

The producer's profit will decease with promotional effort. Thus, under the condition \(\eta \ge H\left({p}_{h}\right)\), the optimal solution of \(\eta\) is the boundary solution, satisfying \(\eta =H\left({p}_{h}\right)\). Substitute it into the profit function \({\pi }_{h}\), we can get,

$$\frac{{d}^{2}{\pi }_{h}}{d{p}_{h}^{2}}=-2\left(1-\delta {o}_{d}\right)<0,\frac{d{\pi }_{h}}{d{p}_{h}}=\left(1-\delta {o}_{d}\right)\left(1-2{p}_{h}\right)-{o}_{d}{p}_{l}.$$
(A-5)

When satisfying the FOC \(\frac{d{\pi }_{h}}{d{p}_{h}}=0\), we obtain \({p}_{h}=\frac{1-\delta {o}_{d}-{o}_{d}{p}_{l}}{2\left(1-\delta {o}_{d}\right)}\).

Assume that the maximum values of \({\pi }_{h}\) under \(\eta \le H\left({p}_{h}\right)\) and \(\eta \ge H\left({p}_{h}\right)\) are \({\pi }_{h1}\) and \({\pi }_{h2}\), respectively. Substitute the optimal decisions into profit functions, we have \({\pi }_{h1}\le {\pi }_{h2}\). Therefore, we can get the unique optimal decisions of price and promotional effort.

1.5 Proof of Property 2

Take the first order partial derivative of \({p}_{h}^{e}\) with respect to \({o}_{d}\), \(\delta\) and \({p}_{l}\), we obtain \(\frac{\partial {p}_{h}^{e}}{\partial {o}_{d}}=-\frac{{p}_{l}}{2{\left(1-\delta {o}_{d}\right)}^{2}}<0\), \(\frac{\partial {p}_{h}^{e}}{\partial \delta }=-\frac{{o}_{d}^{2}{p}_{l}}{2{\left(1-\delta {o}_{d}\right)}^{2}}<0\) and \(\frac{\partial {p}_{h}^{e}}{\partial {p}_{l}}=-\frac{{o}_{d}}{2\left(1-{o}_{d}\right)}<0\). Then, take the first order partial derivative of \({\eta }^{e}\) with respect to \({o}_{d}\), \(\delta\) and \({p}_{l}\), we obtain \(\frac{\partial {\eta }^{e}}{\partial {o}_{d}}=\frac{H\left({o}_{d}\right)}{2{\left(1-\delta {o}_{d}\right)}^{2}}\), \(\frac{\partial {\eta }^{e}}{\partial \delta }=\frac{{o}_{d}\left({\left(1-{o}_{d}\right)}^{2}-{o}_{d}{p}_{l}\right)}{2{\left(1-\delta {o}_{d}\right)}^{2}}\) and \(\frac{\partial {\eta }^{e}}{\partial {p}_{l}}=-\frac{{o}_{d}\left(2-{o}_{d}\right)}{2{\left(1-\delta {o}_{d}\right)}^{2}}<0\). \(H\left({o}_{d}\right)=\delta -\delta {o}_{d}\left(\delta -{p}_{l}\right)(2-\delta {o}_{d})-2{p}_{l}\).

According to \(\frac{\partial H\left({o}_{d}\right)}{\partial {p}_{l}}=\delta {o}_{d}\left(2-\delta {o}_{d}\right)-2\), we can prove that \(H\left({o}_{d}\right)\) is monotonous in range \(\left[0, 1\right]\) with respect to \({p}_{l}\), and \(H\left({o}_{d}=0,{p}_{l}=0\right)=\delta >0\). When \({o}_{d}=1\), we get,

$$H\left({o}_{d}=1,{p}_{l}\right)=-\left(2+{\delta }^{2}-2\delta \right){p}_{l}+\delta {\left(1-\delta \right)}^{2}.$$
(A-6)

Apparently, \(H\left({o}_{d}=1,{p}_{l}\right)\) is negatively related to \({p}_{l}\), \(H\left({o}_{d}=1,{p}_{l}=0\right)=\delta {\left(1-\delta \right)}^{2}>0\), \(H\left({o}_{d}=1,{p}_{l}=\frac{\delta \left(1-\delta \right)}{2-\delta }\right)=\frac{-{\delta }^{2}\left(1-\delta \right)}{2-\delta }<0\). Thus, there is a \(\widehat{{p}_{l}}\) which satisfies \(H\left({o}_{d}=1,{p}_{l}=\widehat{{p}_{l}}\right)=0\) reasonable.

1.6 Proof of Property 3

Take the first order partial derivative of \(C{S}^{e}\) with respect to \({o}_{d}\), we obtain,

$$\frac{\partial C{S}^{e}}{\partial {o}_{d}}=\frac{\left(1+\delta \right){\left(\delta -{p}_{l}\right)}^{2}}{4{\left(1-\delta {o}_{d}\right)}^{2}}{o}_{d}-\frac{\left(\delta -{p}_{l}\right)\left(1+\delta -2{p}_{l}\right)}{4{\left(1-\delta {o}_{d}\right)}^{2}}.$$
(A-7)

The equation above is always lower than 0 in the range of \({o}_{d}\in \left[0, 1\right)\). We further compare the patient's surplus \(C{S}^{e}\) and \(C{S}^{b}\), then get,

$$C{S}^{e}\le C{S}^{e}\left({o}_{d}=0\right)=\frac{{p}_{l}^{2}-\delta {p}_{l}}{2\delta }+\frac{1+\delta }{8}<C{S}^{b}.$$
(A-8)

Compare social welfare in different scenarios \({W}^{e}\) and \({W}^{b}\), get the equation,

$$\Delta \left({p}_{l}\right)={W}^{e}-{W}^{b}=\frac{-{\delta }^{2}{o}_{d}^{3}+\left(6\delta -1\right){o}_{d}^{2}-2\left(2+\delta \right){o}_{d}+1}{8\left(1-\delta \right){\left(1-\delta {o}_{d}\right)}^{2}}{p}_{l}^{2}+\frac{\left(1+\delta \right){o}_{d}-{\delta }^{2}{o}_{d}^{2}-1+\delta }{4\left(1-\delta \right)\left(1-\delta {o}_{d}\right)}{p}_{l}-\frac{{\delta }^{2}{o}_{d}}{8\left(1-\delta \right)}.$$
(A-9)

In the range of \({p}_{l}\in [0,\frac{\delta \left(1-\delta \right)}{2-\delta }]\), the conditions \(\Delta \left(0\right)<0\) and \(\Delta \left(\frac{\delta \left(1-\delta \right)}{2-\delta }\right)<0\) always hold. Because \(\Delta \left({p}_{l}\right)\) is a quadratic function of \({p}_{l}\), the extreme point exists, denoted as \({p}_{l}^{*}\),

$${p}_{l}^{*}=-\frac{\left(1-\delta {o}_{d}\right)\left({\delta }^{2}{o}_{d}^{2}-\delta {o}_{d}-\delta -{o}_{d}+1\right)}{{\delta }^{2}{o}_{d}^{3}-6\delta {o}_{d}^{2}+2\delta {o}_{d}+{o}_{d}^{2}+4{o}_{d}-1}.$$
(A-10)

Substitute (A-10) into \(\Delta \left({p}_{l}\right)\), we can get the extremum in the domain of definition,

$${\Delta }^{*}\left({p}_{l}^{*}\right)=\frac{{\left[1-\delta +{\delta }^{2}{o}_{d}^{2}-\left(1+\delta \right){o}_{d}\right]}^{2}}{8\left(1-\delta \right)\left[{\delta }^{2}{o}_{d}^{3}-\left(1-6\delta \right){o}_{d}^{2}+2\left(2+\delta \right){o}_{d}-1\right]}-\frac{{\delta }^{2}{o}_{d}}{8\left(1-\delta \right)}.$$
(A-11)

According to (A-11), we define a function: \(Den={\delta }^{2}{o}_{d}^{3}-\left(1-6\delta \right){o}_{d}^{2}+2\left(2+\delta \right){o}_{d}-1\). When \(Den<0\), \({\Delta }^{*}\left({p}_{l}^{*}\right)<0\) and \({W}^{e}<{W}^{b}\) always hold. When \(Den>0\), in the range of \(0\le {p}_{l}^{*}\le \frac{\delta \left(1-\delta \right)}{2-\delta }\), \({o}_{d}\) satisfies,

$$\frac{\delta +1-\sqrt{4{\delta }^{3}-3{\delta }^{2}+2\delta +1}}{2{\delta }^{2}}\le {o}_{d}\le \frac{3{\delta }^{2}-4\delta +3-\sqrt{9{\delta }^{4}-32{\delta }^{3}+50{\delta }^{2}-32\delta +9}}{2{\delta }^{2}}.$$
(A-12)

After simplification, we obtain \(\delta \le \frac{2}{3}\). Furthermore, when and only when \({\Delta }^{*}\left({p}_{l}^{*}\right)<0\), the relationship \({W}^{e}<{W}^{b}\) holds, that is,

$$\frac{-4{\delta }^{2}+2\delta +1-\sqrt{16{\delta }^{5}-28{\delta }^{4}+24{\delta }^{3}-16{\delta }^{2}+4\delta +1}}{2{\delta }^{2}\left(3-4\delta \right)}\le {o}_{d}\le \frac{-4{\delta }^{2}+2\delta +1+\sqrt{16{\delta }^{5}-28{\delta }^{4}+24{\delta }^{3}-16{\delta }^{2}+4\delta +1}}{2{\delta }^{2}\left(3-4\delta \right)}.$$
(A-13)

When \(\delta \le 2/3\), Eq. (A-13) always holds.

Compare the relationship between \({p}_{h}^{b}\) and \({p}_{h}^{e}\), \({p}_{h}^{b}-{p}_{h}^{e}=\frac{{p}_{l}\left(1+{o}_{d}-\delta {o}_{d}\right)-\delta (1-\delta {o}_{d})}{2\left(1-\delta {o}_{d}\right)}\). We find when \({p}_{l}>\frac{\delta (1-\delta {o}_{d})}{1+{o}_{d}-\delta {o}_{d}}\), \({p}_{h}^{b}>{p}_{h}^{e}\) holds.

1.7 Proof of Proposition 4

When \(\eta \le H\left({p}_{h}\right)={o}_{d}\left(\delta {p}_{h}-{p}_{l}\right)\), the profit function \({\pi }_{h}\) is monotonically increasing with respect to \({p}_{h}\) based on (A-3). Thus, when \(\overline{p }\le \frac{\eta +{o}_{d}{p}_{l}}{\delta {o}_{d}}\), the optimal pricing decision is \({p}_{h}^{c}=\overline{p }\). Meanwhile, the promotional effort satisfies (A-2). When and only when \(\left(1+{o}_{d}\right)\overline{p }-{o}_{d}{p}_{l}-\left(1-\delta \right){o}_{d}\ge 0\), the condition \(\eta \ge 0\) holds. Therefore, the price cap satisfies \(\overline{p}\ge {P }_{e1}=\frac{{o}_{d}\left(1-\delta +{p}_{l}\right)}{1+{o}_{d}}\), that is, when \(\overline{p}\le {P }_{e1}\), the optimal promotional effort is \({\eta }^{c}=0\).

When \({p}_{h}^{c}=\overline{p }\) and \(\eta =\frac{\left(1+{o}_{d}\right)\overline{p }-{o}_{d}{p}_{l}-\left(1-\delta \right){o}_{d}}{2}>0\), we can obtain the price cap range \({P}_{e1}<\overline{p}\le {P }_{e2}=\frac{{o}_{d}\left(1-\delta -{p}_{l}\right)}{1+{o}_{d}-2\delta {o}_{d}}\) according to \(\eta \le H\left({p}_{h}\right)\).

When \(\overline{p }<{p}_{h}^{e}\), the optimal pricing decision is \({p}_{h}^{c}=\overline{p }\). At this time, the price cap range satisfies \({P}_{e2}<\overline{p}\le {P }_{e3}=\frac{1-\delta {o}_{d}-{o}_{d}{p}_{l}}{2\left(1-\delta {o}_{d}\right)}\) when the promotional effort is \(\eta =H\left({p}_{h}\right)\).

When \(\overline{p }>{P}_{e3}\), the optimal decisions of producer under price cap regulation resembles the situation without price cap policy.

1.8 Proof of Property 4

  1. 1.

    When \(\overline{p}\le {P }_{e1}\), we get \(\frac{dC{S}^{c}}{d\overline{p} }=\frac{\overline{p }-{p}_{l}}{1-\delta }-1\). Thus, \(C{S}^{c}\) monotonically decreases with the price cap \(\overline{p }\) in the range of \(\overline{p }<1-\delta +{p}_{l}\), and monotonically increases in the range of \(\overline{p }>1-\delta +{p}_{l}\). Due to \({P}_{e1}=\frac{{o}_{d}\left(1-\delta +{p}_{l}\right)}{1+{o}_{d}}<1-\delta +{p}_{l}\), when \(\overline{p}\le {P }_{e1}\), there is \(\frac{dC{S}^{c}}{d\overline{p} }<0\). Similarly, according to \(\frac{d{W}^{c}}{d\overline{p} }=-\frac{\overline{p }-{p}_{l}}{1-\delta }\), \(C{S}^{c}\) is monotonically increasing when \(\overline{p }<{p}_{l}\) and monotonically decreasing when \(\overline{p }>{p}_{l}\). Due to \(\overline{p}\ge {p }_{h}>{p}_{l}\), when \(\overline{p}\le {P }_{e1}\), there is \(\frac{d{W}^{c}}{d\overline{p} }<0\).

  2. 2.

    When \({P}_{e1}<\overline{p}\le {P }_{e2}\), we get \(\frac{dC{S}^{c}}{d\overline{p} }=-\frac{\left(1+3{o}_{d}\right)\left(1-{o}_{d}\right)}{4\left(1-\delta \right){o}_{d}^{2}}\overline{p }+\frac{\left(1-3{o}_{d}\right)\left(1-\delta +{p}_{l}\right)}{4\left(1-\delta \right){o}_{d}}\). Therefore, \(C{S}^{c}\) is monotonically increasing in the range of \(\overline{p }<\frac{\left(1-3{o}_{d}\right)\left(1-\delta +{p}_{l}\right)}{\left(1+3{o}_{d}\right)\left(1-{o}_{d}\right)}\) and monotonically decreasing in the range of \(\overline{p }>\frac{\left(1-3{o}_{d}\right)\left(1-\delta +{p}_{l}\right)}{\left(1+3{o}_{d}\right)\left(1-{o}_{d}\right)}\). Because \({P}_{e1}>\frac{\left(1-3{o}_{d}\right)\left(1-\delta +{p}_{l}\right)}{\left(1+3{o}_{d}\right)\left(1-{o}_{d}\right)}\), when \({P}_{e1}<\overline{p}\le {P }_{e2}\), \(\frac{dC{S}^{c}}{d\overline{p} }<0\). Similarly, according to \(\frac{d{W}^{c}}{d\overline{p} }=-\frac{{o}_{d}^{3}+3{o}_{d}^{2}-{o}_{d}+1}{4\left(1-\delta \right){o}_{d}^{2}}\overline{p }+\frac{\left(1-\delta +{p}_{l}\right){o}_{d}^{2}+2{p}_{l}{o}_{d}+1-\delta -{p}_{l}}{4\left(1-\delta \right){o}_{d}}\), \({W}^{c}\) is monotonically increasing when \(\overline{p }<\frac{{o}_{d}\left(\left(1-\delta +{p}_{l}\right){o}_{d}^{2}+2{p}_{l}{o}_{d}+1-\delta -{p}_{l}\right)}{{o}_{d}^{3}+2{o}_{d}^{2}-{o}_{d}+1}\) and monotonically decreasing when \(\overline{p }>\frac{{o}_{d}\left(\left(1-\delta +{p}_{l}\right){o}_{d}^{2}+2{p}_{l}{o}_{d}+1-\delta -{p}_{l}\right)}{{o}_{d}^{3}+2{o}_{d}^{2}-{o}_{d}+1}\). Because of \({P}_{e1}<{P}_{e2}<{P}_{e3}\), the inequality \({P}_{e1}>\frac{{o}_{d}\left(\left(1-\delta +{p}_{l}\right){o}_{d}^{2}+2{p}_{l}{o}_{d}+1-\delta -{p}_{l}\right)}{{o}_{d}^{3}+2{o}_{d}^{2}-{o}_{d}+1}\) always holds. Thus, when \({P}_{e1}<\overline{p}\le {P }_{e2}\), \(\frac{d{W}^{c}}{d\overline{p} }<0\).

  3. 3.

    When \({P}_{e2}<\overline{p}\le {P }_{e3}\), \(\frac{dC{S}^{c}}{d\overline{p} }=\left(1+\delta \right)\overline{p }-1-{p}_{l}\). Then we can obtain that \(C{S}^{c}\) is monotonically decreasing in the range of \(\overline{p }<\frac{1+{p}_{l}}{1+\delta }\) and monotonically increasing in the range of \(\overline{p }>\frac{1+{p}_{l}}{1+\delta }\). Due to \({P}_{e3}<\frac{1+{p}_{l}}{1+\delta }\), when \({P}_{e2}<\overline{p}\le {P }_{e3}\) \(\frac{dC{S}^{c}}{d\overline{p} }<0\). Similarly, based on \(\frac{d{W}^{c}}{d\overline{p} }=-\frac{{{\delta }^{2}{o}_{d}+\left(1-\delta \right)}^{2}}{1-\delta }\overline{p }+\frac{\delta {o}_{d}{p}_{l}}{\left(1-\delta \right)}\), we get that \({W}^{c}\) is monotonically increasing in the range of \(\overline{p }<\frac{\delta {o}_{d}{p}_{l}}{{\delta }^{2}{o}_{d}+{\left(1-\delta \right)}^{2}}\) and monotonically decreasing in the range of \(\overline{p }>\frac{\delta {o}_{d}{p}_{l}}{{\delta }^{2}{o}_{d}+{\left(1-\delta \right)}^{2}}\). Due to \({P}_{e1}<{P}_{e2}<{P}_{e3}\), \({P}_{e2}>\frac{\delta {o}_{d}{p}_{l}}{{\delta }^{2}{o}_{d}+{\left(1-\delta \right)}^{2}}\) always holds. Thus, when \({P}_{e2}<\overline{p}\le {P }_{e3}\), \(\frac{d{W}^{c}}{d\overline{p} }<0\).

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xia, Y., Li, J. & Zhang, Z. Effects of price cap regulation on pharmaceutical supply chain under the zero markup drug policy. Oper Res Int J 23, 56 (2023). https://doi.org/10.1007/s12351-023-00796-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12351-023-00796-4

Keywords

Navigation